Monte Rosa Therapeutics Inc (GLUE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Monte Rosa Therapeutics Inc (GLUE) has a cash flow conversion efficiency ratio of 0.409x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($100.43 Million) by net assets ($245.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Monte Rosa Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Monte Rosa Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Monte Rosa Therapeutics Inc for a breakdown of total debt and financial obligations.
Monte Rosa Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Monte Rosa Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IRSA Inversiones y Representaciones SA
BA:IRSA
|
0.001x |
|
Power HF Co Ltd
SHG:605100
|
0.060x |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
0.020x |
|
Tibet GaoZheng Explosive Co Ltd
SHE:002827
|
0.013x |
|
Hna-Caissa Travel Group Co Ltd
SHE:000796
|
-0.104x |
|
Keystone Reit Ltd
TA:KSTN
|
-0.007x |
|
Advantage Oil & Gas Ltd.
TO:AAV
|
0.048x |
|
Shanghai Prisemi Electronics Co Ltd
SHG:688230
|
0.012x |
Annual Cash Flow Conversion Efficiency for Monte Rosa Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Monte Rosa Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Monte Rosa Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $222.94 Million | $42.00 Million | 0.188x | +177.09% |
| 2023-12-31 | $179.25 Million | $-43.80 Million | -0.244x | +28.27% |
| 2022-12-31 | $271.41 Million | $-92.47 Million | -0.341x | -99.44% |
| 2021-12-31 | $347.51 Million | $-59.36 Million | -0.171x | -136.11% |
| 2020-12-31 | $-48.73 Million | $-23.05 Million | 0.473x | -6.90% |
| 2019-12-31 | $-12.15 Million | $-6.17 Million | 0.508x | -- |
About Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more